Pulmatrix's PUR1900 inhaled CF drug demonstrates potency against fungal infection
Pulmatrix announced preclinical data showing that PUR1900 (iSPERSE™-formulated itraconazole), which is being developed as the first inhaled antifungal medication for CF, was active and potent in vitro against Aspergillus fumigatus, a pathogen causing pulmonary infection. October 08, 2015